Alnylam Pharmaceuticals
(ALNY)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -278,157 | -440,242 | -1,131,156 | -852,824 | -858,281 |
| Depreciation Amortization | 56,670 | 54,054 | 44,468 | 89,694 | 74,435 |
| Income taxes - deferred | -106,762 | -713 | -1,433 | N/A | N/A |
| Accounts receivable | -86,550 | -87,939 | -45,597 | -101,799 | -56,236 |
| Accounts payable and accrued liabilities | 91,093 | 80,840 | 191,769 | 88,240 | 143,732 |
| Other Working Capital | -214,084 | 57,261 | 7,618 | -162,823 | -12,701 |
| Other Operating Activity | 529,478 | 440,895 | 393,057 | 297,819 | 94,090 |
| Operating Cash Flow | $-8,312 | $104,156 | $-541,274 | $-641,693 | $-614,961 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -63,246 | -269,701 | 254,607 | -192,564 | -333,957 |
| PPE Investments | -34,277 | -62,211 | -72,059 | -76,372 | -70,361 |
| Purchase Of Investment | -19,200 | 0 | -8,500 | -166 | -25,900 |
| Other Investing Activity | -117 | -4,438 | -4,694 | -4,198 | -5,300 |
| Investing Cash Flow | $-116,840 | $-336,350 | $169,354 | $-273,300 | $-435,518 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | 135,393 | 500,000 | 200,000 |
| Debt Repayment | N/A | N/A | N/A | 500,000 | 0 |
| Common Stock Issued | 302,951 | 147,464 | 259,360 | 246,268 | 299,982 |
| Other Financing Activity | -8,792 | 24,667 | 31,000 | 850 | 494,997 |
| Financing Cash Flow | $294,159 | $172,131 | $425,753 | $1,247,118 | $994,979 |
| Exchange Rate Effect | -15,239 | 6,391 | -7,430 | -9,018 | 4,918 |
| Beginning Cash Position | 814,884 | 868,556 | 822,153 | 499,046 | 549,628 |
| End Cash Position | 968,652 | 814,884 | 868,556 | 822,153 | 499,046 |
| Net Cash Flow | $153,768 | $-53,672 | $46,403 | $323,107 | $-50,582 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,312 | 104,156 | -541,274 | -641,693 | -614,961 |
| Capital Expenditure | -34,277 | -62,211 | -72,059 | -76,372 | -70,361 |
| Free Cash Flow | -42,589 | 41,945 | -613,333 | -718,065 | -685,322 |